Connect your AI

United Therapeutics UTHR Treasury Stock

Treasury Stock at other companies

Tenet HealthcareTHC

$5.26B+35.2%

Johnson & JohnsonJNJ

$75.86B+0.2%

Merck & Co.MRK

$63.75B+7.3%

ANI PharmaceuticalsANIP

$53M+70.7%

Zevra Therapeutics, Inc.ZVRA

$10.98M0.0%

Other financials

Income statement

Revenue$781.5M-1.6%

Gross profit$648.1M-7.7%

Operating income$325.8M-14.9%

Net income$274.9M-14.7%

EPS (diluted)$5.82-12.2%

Balance sheet

Cash & equivalents$1.3B-32.6%

Total debt$12.2M—

Total equity$5.9B-13.3%

Total assets$6.7B-13.3%

Cash flow

Operating cash flow$463.3M+0.5%

CapEx$100.8M+34.6%

Free cash flow$362.5M-6.2%

Valuation

Market cap$26.32B+95.7%

P/E20.4×+9.6×

P/S8.3×+3.9×

Profitability

Gross margin86.6%-2.4pp

Operating margin45.3%-1.6pp

Net margin40.6%+0.2pp

FCF margin32.1%-5.6pp

Returns & leverage

Return on equity20.3%+0.3pp

Debt / equity0×—

Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is United Therapeutics's treasury stock?: United Therapeutics (UTHR) reported treasury stock of $5.44B in Q1 2026.
How has United Therapeutics's treasury stock changed year-over-year?: United Therapeutics's treasury stock increased by 56.6% year-over-year, from $3.47B to $5.44B.
What is the long-term trend for United Therapeutics's treasury stock?: Over 5 years (2020 to 2025), United Therapeutics's treasury stock has grown at a 10.6% compound annual growth rate (CAGR), from $2.58B to $4.26B.
What does treasury stock mean?: Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.